25CN-NBOMe, also known as 2C-CN-NBOMe or NBOMe-2C-CN, is a derivative of the phenethylamine 2C-CN. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the serotonin 5-HT2A receptor.

Interactions

Pharmacology

Pharmacodynamics

25CN-NBOMe activities
TargetAffinity (Ki, nM)
5-HT1AND
5-HT1BND
5-HT1DND
5-HT1END
5-HT1FND
5-HT2A1.8–4.6 (Ki) 0.40–6.7 (EC50Tooltip half-maximal effective concentration) 77–148% (EmaxTooltip maximal efficacy)
5-HT2B21–47 (Ki) 12 (EC50) 79% (Emax)
5-HT2C8–180 (Ki) 9.3–230 (EC50) 91–101% (Emax)
5-HT3ND
5-HT4ND
5-HT5AND
5-HT6145
5-HT7ND
α1Aα1DND
α2Aα2CND
β1β3ND
D1D5ND
H1H4ND
M1M5ND
I1ND
σ1, σ2ND
ORsND
TAAR1Tooltip Trace amine-associated receptor 1ND
SERTTooltip Serotonin transporterND (Ki) ND (IC50Tooltip half-maximal inhibitory concentration) ND (EC50)
NETTooltip Norepinephrine transporterND (Ki) ND (IC50) ND (EC50)
DATTooltip Dopamine transporterND (Ki) ND (IC50) ND (EC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:

25CN-NBOMe acts as a potent and selective agonist of the serotonin 5-HT2A receptor. To a lesser extent, it also acts as an agonist of the serotonin 5-HT2B and 5-HT2C receptors.

History

25CN-NBOMe was first described in the scientific literature by 2010.

Society and culture

Legal status

Canada

25CN-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.

See also

External links